Advisory Cmte. Package Redaction Could Add Two Months To Priority Review
Executive Summary
A drug receiving six-month priority review could have its review time extended by up to two months if its sponsor requests redaction of the advisory committee package, FDA said in a draft guidance.
You may also be interested in...
Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA
Portions of postmarketing study annual status reports that will be publicly disclosed should be pre-specified by study sponsors, the Pharmaceutical Research and Manufacturers of America told FDA in Feb. 14 comments.
Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA
Portions of postmarketing study annual status reports that will be publicly disclosed should be pre-specified by study sponsors, the Pharmaceutical Research and Manufacturers of America told FDA in Feb. 14 comments.
Celebrex information disclosure
FDA must release to Public Citizen's Health Research Group the raw patient data in Searle's Celebrex advisory committee packet, following a Jan. 19 summary judgement by Washington D.C. federal court Judge James Robertson that the information is not covered by Freedom of Information Act exemptions. HRG's request for release of names of Searle's scientific investigators and titles of unpublished articles by Searle investigators submitted to FDA was denied. Public disclosure of advisory committee materials was mandated under a July settlement with HRG, though the agency may redact material it considers confidential (1"The Pink Sheet" Jan. 3, p. 21)